850090-13-0

Basic information

• Product Name: Tos-PEG3-t-butyl ester
• Synonyms: Tos-PEG3-t-butyl ester;Tos-PEG2-CH2CH2COOtBu
• CAS NO: 850090-13-0
• Molecular Formula: C₁₈H₂₈O₇S
• Molecular Weight: 388.48
• Mol File: 850090-13-0.mol

Chemical Properties

• Boiling Point: 495.2±35.0 °C(Predicted)
• Appearance: /
• Density: 1.159±0.06 g/cm3(Predicted)
• CAS DataBase Reference: Tos-PEG3-t-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Tos-PEG3-t-butyl ester(850090-13-0)
• EPA Substance Registry System: Tos-PEG3-t-butyl ester(850090-13-0)

Safety Data

• Hazardous Substances Data: 850090-13-0(Hazardous Substances Data)

Usage

Uses

Used in Chemical Synthesis:
Tos-PEG3-t-butyl ester is used as a protecting group in chemical synthesis for carboxyl-containing compounds. The t-butyl ester provides a stable and easily removable protection under acidic conditions, facilitating the synthesis of complex molecules.
Used in Drug Delivery Systems:
In the pharmaceutical industry, Tos-PEG3-t-butyl ester is used as a component in drug delivery systems. The hydrophilic PEG spacer enhances the solubility and stability of drug molecules in aqueous environments, while the t-butyl ester allows for controlled release of the active pharmaceutical ingredient under specific conditions.
Used in Bioconjugation:
Tos-PEG3-t-butyl ester is utilized as a bioconjugation agent to attach biologically active molecules, such as peptides or proteins, to other molecules or surfaces. The tosyl group's reactivity in nucleophilic substitution reactions enables the formation of stable covalent bonds with a variety of nucleophiles, making it suitable for creating bioconjugates with specific functionalities.
Used in Surface Modification:
In materials science, Tos-PEG3-t-butyl ester is used for surface modification of various substrates, such as nanoparticles or polymers. The PEG spacer improves the hydrophilicity and biocompatibility of the modified surfaces, while the t-butyl ester and tosyl group provide reactive sites for further functionalization or immobilization of specific molecules.

Upstream product

• 133803-81-3 2-methyl-2-propanyl 3-[2-(2-hydroxyethoxy)ethoxy]propanoate 
• 1663-39-4 tert-Butyl acrylate 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 1312309-63-9 3-(2-(2-azidoethoxy)ethoxy)propanoic acid 
• 1271728-79-0 tert-butyl 3-(2-(2-azidoethoxy)ethoxy)propanoate 
• 1938057-43-2 tert-butyl 3-(2-(2-iodoethoxy)ethoxy)propanoate 
• 1398044-50-2 C₁₁H₂₂O₄S 

Relevant articles and documents

Synthesis of KUE-siRNA Conjugates for Prostate Cancer Cell-Targeted Gene Silencing

The delivery of siRNAs to selectively target cells poses a great challenge in RNAi-based cancer therapy. The lack of suitable cell-targeting methods seriously restricts the advance in delivering siRNAs to extrahepatic tissues. Based on prostate-specific m

Design, Synthesis, and Evaluation of WD-Repeat-Containing Protein 5 (WDR5) Degraders

Histone H3K4 methylation serves as a post-translational hallmark of actively transcribed genes and is introduced by histone methyltransferase (HMT) and its regulatory scaffolding proteins. One of these is the WD-repeat-containing protein 5 (WDR5) that has also been associated with controlling long noncoding RNAs and transcription factors including MYC. The wide influence of dysfunctional HMT complexes and the typically upregulated MYC levels in diverse tumor types suggested WDR5 as an attractive drug target. Indeed, protein-protein interface inhibitors for two protein interaction interfaces on WDR5 have been developed. While such compounds only inhibit a subset of WDR5 interactions, chemically induced proteasomal degradation of WDR5 might represent an elegant way to target all oncogenic functions. This study presents the design, synthesis, and evaluation of two diverse WDR5 degrader series based on two WIN site binding scaffolds and shows that linker nature and length strongly influence degradation efficacy.

Conjugate and preparation method and application thereof

The invention relates to the technical field of biology, and discloses a conjugate and a preparation method and application thereof. The conjugate is formed by covalent attachment of a nitrogen-azide modified targeting ligand and a propargyl-modified smal

TARGET PROTEIN EED DEGRADATION-INDUCING DEGRADUCER, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATED TO EED, EZH2, OR PRC2, COMPRISING SAME AS ACTIVE INGREDIENT

The present invention relates to a target protein degradation-inducing Degraducer, a preparation method thereof, and a pharmaceutical composition for preventing or treating diseases related to EED, EZH2, or PRC2 comprising same as an active ingredient. A novel compound represented by formula 1, according to the present invention is a Degraducer compound that induces degradation of a target protein, i.e., embryonic ectoderm development (EED) or polycomb repressive complex 2 (PRC2), utilizing cereblon E3 ubiquitin ligase, von Hippel-Lindau tumor suppressor (VHL) E3 ubiquitin ligase, mouse double minute 2 homolog (MDM2) E3 ubiquitin ligase, and cellular inhibitor of apoptosis protein 1 (cIAP) E3 ubiquitin ligase, wherein the compound has an aspect of remarkably achieving target protein degradation-inducing activity through a ubiquitin proteasome system (UPS), and therefore there is a useful effect in that it is possible to provide a pharmaceutical composition for preventing or treating diseases or conditions related to a target protein, and a functional health food composition for preventing or improving same, comprising said compound as an active ingredient.

Systematic Investigation of the Permeability of Androgen Receptor PROTACs

Bifunctional molecules known as PROTACs simultaneously bind an E3 ligase and a protein of interest to direct ubiquitination and clearance of that protein, and they have emerged in the past decade as an exciting new paradigm in drug discovery. In order to investigate the permeability and properties of these large molecules, we synthesized two panels of PROTAC molecules, constructed from a range of protein-target ligands, linkers, and E3 ligase ligands. The androgen receptor, which is a well-studied protein in the PROTAC field was used as a model system. The physicochemical properties and permeability of PROTACs are discussed.

CROSS-LINKED PYRROLOBENZODIAZEPINE DIMER (PBD) DERIVATIVE AND ITS CONJUGATES

A novel cross-linked cytotoxic agents, pyrrolobenzo-diazepine dimer (PBD) derivatives, and their conjugates to a cell-binding molecule, a method for preparation of the conjugates and the therapeutic use of the conjugates.

CONJUGATION LINKERS CONTAINING 2,3-DIAMINOSUCCINYL GROUP

Provided is a conjugate of a cytotoxic drug/molecule to a cell-binding molecule with a bis-linker (adual-linker) containing a 2, 3-diaminosuccinyl group. It also relates to preparation of the conjugate of a cytotoxic drug/molecule to a cell-binding molecule with the bis-linker, particularly when the drug having functional groups of amino, hydroxyl, diamino, amino-hydroxyl, dihydroxyl, carboxyl, hydrazine, aldehyde and thiol for conjugation with the bis-linker in a specific manner, as well as the therapeutic use of the conjugates.

New fluorine-18 pretargeting PET imaging by bioorthogonal chlorosydnone-cycloalkyne click reaction

We report the first pretargeting in vivo study using the Strain-Promoted Sydnone-Alkyne Cycloaadition (SPSAC) reaction. The injection of a fluorine-18 labeled cyclooctyne three days after cetuximab bearing chlorosydnone moieties allowed a significant detection of the tumor by PET imaging suggesting an efficient click reaction inside the tumoral site. With a kinetic constant superior to 300 M-1 s-1, the SPSAC reaction might be an interesting tool, in addition to tetrazine-cyclooctene ligation, for in vivo chemistry.

Identification of New Small-Molecule Inducers of Estrogen-related Receptor α (ERRα) Degradation

A series of (E)-3-(4-((2,4-bis(trifluoromethyl)benzyl)oxy)-3-methoxyphenyl)-2-cyanoacrylamide derivatives were designed and synthesized as new estrogen-related receptor α (ERRα) degraders based on the proteolysis targeting chimera (PROTAC) concept. One of the representative compounds 6c is capable of specifically degrading ERRα protein by >80% at a relatively low concentration of 30 nM, becoming one of the most potent and selective ERRα degraders to date. Compound 6c could be utilized as a new powerful research tool for further biological investigation of ERRα.

CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE

What provided is the conjugation of cytotoxic to a cell-binding molecule with a bis-linker(dual-linker) as shown in Formula (I). It provides bis-linkage methods of making a conjugate of a cytotoxic drug molecule to a cell-binding agent in a specific manner. It also relates to application of the conjugates for the treatment of a cancer, or an autoimmune disease, or an infectious disease.